Genscript Biotech Crp Ord (GNNSF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to Genscript Biotech 2026 Interim Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, CFO of Jamescript Biotech Group, Mr. Phil Zhao. Please go ahead. Welcome to our 2026 Interim Results Conference call. Joining me on the call today are Mr. Robin Munn, Chairman of the Board, Mr. Sherry Shao, Locating CEO of Genescript, Dr. Rui Chen, President of Genescript Life Science Group, Dr. Icy Bai, General Manager of BestSign, and Mr. Alan Wolk, CEO of Propel. During today's call, we will be making statements about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, which may constitute overlooking statements. Actual results may differ materially from those indicated by such overlooking statements because of various important risk factors and changing marketing conditions. We do not undertake any obligation to publicly update any overlooking statements. Before we begin, please note that the prior period of figures presented in this conference hall are on a comparable basis, excluding the financial impact of the license transaction with Lenovo pursuant to the license agreement that was recognized in the prior period. We believe this provides a more objective view of the group's underlying business performance. Today...